Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 1997

View Archived Issues

Betulinic acid derivatives reported to have anti-HIV activity

Pfizer claims glycogen phosphorylase inhibitors

Piperidine derivatives reported by Schering-Plough

AHP claims smooth muscle cell proliferation inhibitors

Merck & Co. continues to develop farnesyl protein transferase inhibitors

Aminoisoindole derivatives discovered for neuropsychological disorders

A new class of GABA receptor ligands claimed by Neurogen

Novel diabetes treatments reported by Shaman

Hoechst develops antipsychotic agents

Takeda's new cephems

1996 in review: Adcock Ingram

Antineoplastic antibiotics isolated by Japanese investigators

Hepatoprotective activity of Chinese medicine tested in animal models

Progenics awarded grants to develop HIV therapeutics

Demeter receives funding for anticancer program

Pharma Patch restructures

Patent coverage sought for novel approach to reducing side effects of vitamin A

Marnac licenses broad-spectrum antifibrotic drug

Pall Corporation finalizes acquisition

GelMed receives patent coverage for new use of polymers

Golden and Syncor sign letter of intent

Positive results reported from TOBI pivotal trials

Cytogen/Elan oral drug delivery collaboration advances

GeneMedicine IND approved

U.S. patent for Tularik drug discovery assays

Tularik receives patent coverage for protein involved in immune response

ICOS/Glaxo Wellcome collaboration modified

U.S. launch for prostate cancer imaging agent

Gen-Probe diagnostic approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...